TP53 and neoplasm: CNV analysis performed in patients with a tumour infiltration ≥20% (65%) determined at least one CNV in 83% patients with most deletions in RB1, ATM, CDKN2A/B and TP53 and most amplifications in KLF2, CXCR4, CCND1, MAP2K1 and MYC. This is in line with previously reported findings in the EMCL study cohort and others [5, 9].